半胱氨酰白三烯受体拮抗剂对成人哮喘的临床疗效观察

目的 系统观察半胱氨酰白三烯（CysLTs）受体拮抗剂安可来在不同严重程度哮喘患者中的疗效及其安全性。方法 117例成人哮喘患者,其中轻度哮喘62例,中度哮喘34例,重度哮喘21例。口服安可来20mg,2次／d,持续服用4周。结果 轻、中、重度哮喘患者口服安可来后日间及夜间症状计分、液间憋醒次数、吸入β2－受体激动剂用量及肺功能指标包括FEV1（轻度患者除外）、PEFRam、PEFRpm均有显著改善,与安可来相关的可颖药物发生不良反应5例（4％）,症状轻微,无需特别处理。结论 安可来对各种严重程度哮喘均具有缓解哮喘症状及改善肺功能的作用,且具有服用方便、副作用少、耐受性好的优点。

Effects of cysteinylleukotriene receptor antagonist (Accolate)on patients with asthma

Objective　To evaluate the efficancy and safety of oral Accolate, a cysteinyl leukotriene receptor antagonist,in patients with mild to severe asthma in a multicenter, opening study.Methods　117 patients (mean aged 41±13 yrs, M 57, F 60; mild asthma 62, moderate asthma 34, severe asthma 21) received 20mg Accolate twice daily for 4 weeks.Results　FEV1、PEFRam、PEFRpm increased significantly as well as daytime asthma score,nighttime asthma score,nighttime awaken time and additional inhaled bronchodilator usage improved significantly in all of mild、moderate and severe asthmatics. Drug-related adverse effects were observed in 5 cases(4%).But all of these adverse effects were slight and didn't necessitate discontinuation of therapy.Conclusion　The results of our study suggest that Accolate improve lung function and symptoms in mild to severe asthmatics with an excellent tolerability profile.